In the latest blow to the University of California San Diego (UCSD) in its fight with the University of Southern California, the Eli Lilly and Company has reportedly decided to end its contract with the university for management of a landmark Alzheimer's study.
The development may cost million of dollars to the UCSD. The battle is for an A4 study, clinical trial testing solanezumab in the preclinical stage of Alzheimer's disease in older individuals.
The study has been managed by the Alzheimer's Disease Cooperative Study at UCSD. The study is funded by the Eli Lilly and Company, the National Institutes of Health and multiple philanthropic organizations.
Many members of the ADCS staff left UCSD this summer to join USC - sparking a UCSD lawsuit.
Recently, Judge Judith Hayes ruled that UCSD controlled the nationwide study, indicating that UCSD likely would prevail if the case went to trial.
But, last week, USC filed a countersuit against UCSD to try to regain control of the study.